Inflammatory bowel disease and medical assessment service

Czech version

Authors: Matějková P. ^1,2; Vítková Z. ²
Authors‘ workplace: Sanatorium sv. Anny, Gastroenterologie, EGK, s. r. o., Praha ¹; ČSSZ, Oddělení lékařské posudkové služby, pracoviště pro Prahu a střední Čechy, Praha ²
Published in: Gastroent Hepatol 2019; 73(1): 37-42
Category: IBD: Review Article
doi: https://doi.org/10.14735/amgh201937

Overview

This article discusses the relationship between inflammatory bowel disease (IBD) and the medical assessment service (MAS). It discusses the general competence of the MAS and its co-operation with general practitioners and gastroenterologists. It also describes the process of assessment in general, and assessment of IBD patients in accordance with valid regulations. The statistical data identify the proportion of patients assessed by the MAS who had gastroenterologic disease, and the proportion of patients from that group that had IBD. The data also reflect changes in the number of disability requests between 2015 and 2017, and the results of IBD patient assessments, including gender and age. The authors also discuss the costs of disability associated with IBD.

Key words:

inflammatory bowel disease – medical assessment service – disability

Submitted: 17. 1. 2019

Accepted: 3. 2. 2019

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Sources

1. Sonnenberg A. Disability from inflammatory bowel disease among employees in west Germany. Gut 1989; 30(3): 367– 370. doi: 10.1136/ gut.30.3.367.

2. Bernklev T, Jahnsen J, Henriksen M. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12(5): 402– 412. doi: 10.1097/ 01.MIB.0000218762.61217.4a.

3. Lönnfors S, Vermeire S, Greco M et al. IBD and health-related quality of life – discovering the true impact. J Crohns Colitis 2014; 8(10): 1281– 1286. doi: 10.1016/ j.crohns.2014.03. 005.

4. Ueno F, Nakayama Y, Hagiwara E et al. Impact of inflammatory bowel disease on Japanese patients‘ quality of life: results of a patient questionnaire survey. J gastroenterol 2017; 52(5): 555– 567. doi: 10.1007/ s00535-016-1241-x.

5. Büsch K, da Silva SA, Holton M et al. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis 2014; 8(11): 1362– 1377. doi: 10.1016/ j.crohns.2014.06.006

6. Ďuricová D, Pfeiferová M, Bortlík M et al. Kvalita života pacientů s idiopatickými střevními záněty v České republice – multicentrická studie. Gastroent Hepatol 2018; 72(1): 11– 19. doi:10.14735/ amgh201811.

7. Česká správa sociálního zabezpečení. Výroční zpráva ČSSZ za rok 2016. [online]. Dostupné z: www.cssz.cz/ cz/ o-cssz/ informace/ informacni-materialy/ vyrocni-zpravy.htm.

8. Vyhláška č. 359/ 2009 Sb., kterou se stanoví procentní míry poklesu pracovní schopnosti a náležitosti posudku o invaliditě a upravuje posuzování pracovní schopnosti pro účely invalidity (vyhláška o posuzování invalidity). [online]. Dostupné z: www.cssz.cz/ NR/ rdonlyres/ 8000A7B2-7C7A-4C83-A6AF-5C941D68CEE5/ 0/ 359_2009_1.pdf.

9. Burisch J, Jess T, Martinato M et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013; 7(4): 322– 337. doi: 10.1016/ j.crohns.2013.01.010.

10. Jarkovský J, Benešová K, Hejduk K. Epidemiologie, hospitalizační léčba a migrace IBD pacientů za specializovanou péčí v České republice. Gastroent Hepatol 2017; 71(6): 501– 5169. doi:10.14735/ amgh2017501.